Peyronie's disease

Renowned Los Angeles Urologist Dr. Justin Houman Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Wednesday, March 20, 2024

LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist, as Assistant Professor in the esteemed Department of Urology. With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.

Key Points: 
  • Dr. Justin Houman, M.D., brings expertise in clinical care, research, and medical education to Cedars-Sinai's Department of Urology.
  • LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist , as Assistant Professor in the esteemed Department of Urology.
  • With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.
  • In his role as Assistant Professor, Dr. Houman will impart invaluable knowledge and mentorship to medical students, residents, and fellows in urology.

Jelqing: the latest in a long history of attempts to enlarge the male member

Retrieved on: 
Thursday, February 15, 2024

Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.

Key Points: 
  • Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.
  • Jelqing is just the latest in a long line of dubious penis enlargement techniques stretching (sorry) back millennia.
  • The ancient Greek method of lengthening the foreskin with a kynodesme (dog leash) seems positively mild compared with ancient Indian methods.
  • Penis pumps are also used for erectile dysfunction, but unlike some online claims, they don’t lengthen the penis.

Surgical interventions

  • Fillers are increasing in popularity, particularly hyaluronic acid (HA) injections.
  • HA is popular because it is doesn’t generate an immune response.
  • Surgery to cut the suspensory ligament anchoring the penis is the most widely accepted surgical elongation method.
  • A recent review concluded that evidence for supporting surgical procedures for penis enlargement is weak and the complications are under-reported.

Not needed, in most cases

  • A micropenis, usually diagnosed at birth, is where the penis is 2.5 standard deviations less than the average stretched penis length (2.3 to 2.5cm depending on ethnicity).
  • It is typically caused by a deficiency or imbalance of hormones such as testosterone or human chorionic gonadotropin (hCG), or genetics.
  • The female vagina is on average 2.5 to 3.8 inches deep, but lengthens during sexual arousal to accommodate a penis longer than this.
  • The female genitalia have multiple erogenous structures that can result in orgasm, so penile length isn’t the key characteristic.

A closer look at jelqing

  • The top two consist of numerous spaces that are surrounded by smooth muscle, which keeps most blood out of the spaces.
  • During an erection, the muscles relax allowing blood to flow in, filling these spaces, and enlarging penile volume.
  • While the theory sounds good, smooth muscle cells in the penis don’t respond in the same way skeletal muscle does.
  • If jelqing, or any other trend, was really that effective, we would have seen evidence of it in medical journals, and the sale of extra-large underwear would be making the headlines.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Los Angeles Vasectomy and Vasectomy Reversal Specialist, Dr. Justin Houman, is Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Tuesday, January 23, 2024

LOS ANGELES, Jan. 23, 2024 /PRNewswire-PRWeb/ -- As an esteemed assistant professor in urology at Cedars-Sinai Medical Center, Dr. Justin Houman will continue enhancing the quality of life for men by improving their sexual, reproductive and hormonal health. Dr. Houman provides his patients with the latest and most effective treatments available, with extensive expertise in vasectomy, vasectomy reversal, infertility, testosterone, Peyronie's disease, erectile dysfunction and urology. Also, as a top minimally invasive microscopic surgeon, Dr. Houman delivers skill and expertise in microsurgical varicocelectomies, vasectomy reversals, sperm retrievals, penile implants and male incontinence. His vast knowledge and experience in urology have earned him recognition as a leading authority in men's health. Dr. Houman's appointment at Cedars-Sinai Medical Center is a testament to his exceptional skills, dedication and unwavering commitment to patient care. As an assistant professor, Dr. Houman will continue to contribute to the advancement of urological research and education for his patients and students.

Key Points: 
  • Board-certified and fellowship-trained urologist, Dr. Justin Houman, is a top men's health specialist and leading urological surgeon in the Los Angeles area.
  • LOS ANGELES, Jan. 23, 2024 /PRNewswire-PRWeb/ -- As an esteemed assistant professor in urology at Cedars-Sinai Medical Center, Dr. Justin Houman will continue enhancing the quality of life for men by improving their sexual, reproductive and hormonal health.
  • Dr. Houman provides his patients with the latest and most effective treatments available, with extensive expertise in vasectomy, vasectomy reversal , infertility, testosterone, Peyronie's disease, erectile dysfunction and urology.
  • Dr. Houman's appointment at Cedars-Sinai Medical Center is a testament to his exceptional skills, dedication and unwavering commitment to patient care.

Los Angeles Vasectomy and Vasectomy Reversal Specialist, Dr. Justin Houman, Recognized as a 2024 Top Patient Rated Doctor by Find Local Doctors

Retrieved on: 
Monday, January 8, 2024

LOS ANGELES, Jan. 8, 2024 /PRNewswire-PRWeb/ -- Dr. Justin Houman, a highly esteemed board-certified urologist and renowned men's health specialist, has received the Top Patient Rated Doctor award from Find Local Doctors. This recognition is a result of his five-star ratings and exceptional reviews from patients. Find Local Doctors is a trusted online directory that allows patients to locate and connect with the best physicians in their area. Dr. Houman's practice offers a comprehensive approach to men's health, specializing in the diagnosis and treatment of various urological conditions. With his expertise and commitment to patient care, he has become a trusted authority in his field. Dr. Houman's state-of-the-art practice is centered on enhancing his patients' quality of life through comprehensive male urology. He specializes in male fertility, erectile dysfunction, sexual performance, testosterone management and Peyronie's disease. The clinic has been recognized as a Xiaflex Center of Excellence for the treatment of Peyronie's disease. Also, as a top minimally invasive microscopic surgeon, Dr. Houman provides skill and expertise in microsurgical varicocelectomies, vasectomy reversals, sperm retrievals, penile implants and male incontinence.

Key Points: 
  • LOS ANGELES, Jan. 8, 2024 /PRNewswire-PRWeb/ -- Dr. Justin Houman, a highly esteemed board-certified urologist and renowned men's health specialist, has received the Top Patient Rated Doctor award from Find Local Doctors.
  • Find Local Doctors is a trusted online directory that allows patients to locate and connect with the best physicians in their area.
  • Dr. Houman's practice offers a comprehensive approach to men's health, specializing in the diagnosis and treatment of various urological conditions.
  • Dr. Justin Houman's clinic is located at 8635 W 3rd St, Suite 1W in Los Angeles, CA.

Endo Launches Unscripted Video Series With Real Peyronie's Disease Patients

Retrieved on: 
Thursday, November 30, 2023

DUBLIN, Nov. 30, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today the launch of its new branded video series, PD Pool Hall, which aims to educate people about Peyronie's disease (PD), a men's health condition that is estimated to affect 1 in 10 men in the U.S.* and can lead to a curvature deformity of the penis when erect.

Key Points: 
  • The PD Pool Hall videos feature four real patients, both treated and untreated, in a pool hall discussing their experiences with PD, including the impact on their lives and their treatment journeys.
  • The conversations are unscripted and present the patients' actual views and stories.
  • "The men in the videos know firsthand the confusion, embarrassment and even fear that men may face along the PD journey," Mattice continued.
  • The videos are viewable on Endo's newly redesigned consumer website for XIAFLEX, found at XIAFLEX.com .

Endo Launches Unscripted Video Series With Real Peyronie's Disease Patients

Retrieved on: 
Thursday, November 30, 2023

DUBLIN, Nov. 30, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today the launch of its new branded video series, PD Pool Hall, which aims to educate people about Peyronie's disease (PD), a men's health condition that is estimated to affect 1 in 10 men in the U.S.* and can lead to a curvature deformity of the penis when erect.

Key Points: 
  • The PD Pool Hall videos feature four real patients, both treated and untreated, in a pool hall discussing their experiences with PD, including the impact on their lives and their treatment journeys.
  • The conversations are unscripted and present the patients' actual views and stories.
  • "The men in the videos know firsthand the confusion, embarrassment and even fear that men may face along the PD journey," Mattice continued.
  • The videos are viewable on Endo's newly redesigned consumer website for XIAFLEX, found at XIAFLEX.com .

Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting

Retrieved on: 
Thursday, November 16, 2023

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.
  • "The relatively common condition of Peyronie's disease—estimated to affect 1 in 10 men in the U.S.—remains under-studied and is often misunderstood," said Dr. Jesse Mills, urologist and presenter of the data analysis poster.
  • "Efforts like the post hoc analysis of XIAFLEX® Phase 3 data and the new landmark registry aim to advance medical knowledge of PD and support patient outcomes."
  • The five new Endo-sponsored and Endo-supported presentations are below:
    Peyronie's Disease Patients with Penile Pain at Baseline Treated with Collagenase Clostridium Histolyticum: A Post Hoc Analysis
    Outcomes of Collagenase Clostridium Histolyticum in Men with Ventral Curvatures: An Updated Series
    Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study
    Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial – 1 Year Outcomes

Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting

Retrieved on: 
Thursday, November 16, 2023

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the Sexual Medicine Society of North America (SMSNA) annual meeting, taking place November 16-19 in San Diego.
  • "The relatively common condition of Peyronie's disease—estimated to affect 1 in 10 men in the U.S.—remains under-studied and is often misunderstood," said Dr. Jesse Mills, urologist and presenter of the data analysis poster.
  • "Efforts like the post hoc analysis of XIAFLEX® Phase 3 data and the new landmark registry aim to advance medical knowledge of PD and support patient outcomes."
  • The five new Endo-sponsored and Endo-supported presentations are below:
    Peyronie's Disease Patients with Penile Pain at Baseline Treated with Collagenase Clostridium Histolyticum: A Post Hoc Analysis
    Outcomes of Collagenase Clostridium Histolyticum in Men with Ventral Curvatures: An Updated Series
    Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study
    Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial – 1 Year Outcomes

Endo Announces First Patient Enrolled in Registry of Peyronie's Disease

Retrieved on: 
Thursday, July 20, 2023

DUBLIN, July 20, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to 1,000 patients with Peyronie's disease (PD).

Key Points: 
  • DUBLIN, July 20, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to 1,000 patients with Peyronie's disease (PD).
  • This registry will create the largest and most comprehensive collection of real-world PD data on treatment outcomes.
  • "Along with our study steering committee partners, Endo is committed to supporting the Peyronie's patient community."
  • "This landmark registry will facilitate more comprehensive knowledge of treatment and management using real-world evidence."

Endo Announces First Patient Enrolled in Registry of Peyronie's Disease

Retrieved on: 
Thursday, July 20, 2023

DUBLIN, July 20, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to 1,000 patients with Peyronie's disease (PD).

Key Points: 
  • DUBLIN, July 20, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to 1,000 patients with Peyronie's disease (PD).
  • This registry will create the largest and most comprehensive collection of real-world PD data on treatment outcomes.
  • "Along with our study steering committee partners, Endo is committed to supporting the Peyronie's patient community."
  • "This landmark registry will facilitate more comprehensive knowledge of treatment and management using real-world evidence."